Vanda Pharmaceuticals develops and sells prescription medicines for psychiatric, sleep and neurological conditions. It last closed at $3.81 on Nov 17, up 0.00% on the day. VNDA reports earnings on Wed, Feb 10, 2027.
Only 1 firm rated VNDA in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 162.5% upside
Based on 1 analyst who set a price target on VNDA in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $3.81.
Low $10.00Avg $10.00High $10.00
Blue marker: last close $3.81
Highest target$10.00
Average target$10.00
Lowest target$10.00
Latest rating changes
OppenheimerInitiated
Sep 23Buy$10
B. Riley SecuritiesReiterated
Aug 10Buy$12
HC Wainwright & Co.Maintained
Aug 10Buy$20
Date
Firm
Action
Rating
Price target
Sep 23
Oppenheimer
Initiated
Buy
$10
Aug 10
B. Riley Securities
Reiterated
Buy
$12
Aug 10
HC Wainwright & Co.
Maintained
Buy
$20
Loading…
Whale Options Flow
90D
No whale options trades in VNDA in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VNDA is in one of them and how their past VNDA trades turned out.
Vanda Pharmaceuticals is a biopharmaceutical company based in Washington, D.C. It develops and sells prescription medicines for patients with psychiatric, sleep and neurological conditions. Its marketed products include Fanapt for schizophrenia and bipolar I disorder, HETLIOZ for certain sleep-wake disorders, PONVORY for multiple sclerosis, and NEREUS for preventing vomiting caused by motion. The company also has other medicines in development.